In brief
After twin attempts to kill death row inmate Christa Pike with lethal injections failed, Tennessee governor Bill Lee halted all executions for the rest of 2026. Pike, convicted in 1996 for murder, survived two injections and was rushed to a hospital. Lee cited the incident as a major disappointment and ordered a third‑party review of the state’s execution procedure. The pause coincides with an upcoming execution of Gary Sutton, raising questions over Tennessee’s capital punishment future. This marks the second botched execution in the state this year.
Tennessee halts executions after death row inmate Christa Pike survives lethal injection attempt
The Tennessee governor announced that all executions would be suspended for the remainder of the year following two failed lethal‑injection attempts on 50‑year‑old Christa Pike.
Pike was convicted in 1996 for the murder of Colleen Slemmer and was slated to be the first woman executed in Tennessee in over two centuries.
The state reported that the first dose of the lethal drug, a pentobarbital mixture, did not trigger the expected reaction. A second attempt was also unsuccessful, leaving Pike unconscious but alive and transported to a hospital without a clear diagnosis.
Governor Bill Lee called the incident “highly disappointing” and ordered a third‑party review to determine the cause of the botched execution. The review’s scope and lead remain to be named.
The administration cited that its protocol had always been “lawful and established.” Yet Pike’s legal team has demanded life‑saving measures, arguing that the execution was a failure.
The pause coincides with the scheduled execution of convicted murderer Gary Sutton on 3 December, raising questions about the future of capital punishment in the state.
This marks the second botched execution attempt in Tennessee in 2026, after a similar incident involving Tony Carruthers earlier this year, when staff could not locate a vein to administer the lethal drug.
Legally, the state claims the protocol is exhaustive; however, critics argue the use of pentobarbital, once reliable, has become controversial amid shortages and calls for reform.
